Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl
Hematopoietic Stem Cells
Protein Kinase Inhibitors
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info